Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.68 |
| ▸ | HTR2A | P28223 | 4/20 | 0.57 |
| ▸ | HTR6 | P50406 | 10/20 | 0.48 |
| ▸ | HTR1D | P28221 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL847974 | 0.81 | HTR2C (0.68) | HTR2CHTR2AHTR6HTR1DCNR2 | |
| SCHEMBL23956102 | 0.81 | HTR2C (0.68) | HTR2CHTR2AHTR6HTR1DCNR2 | |
| SCHEMBL1990730 | 0.81 | HTR2C (0.44) | HTR2CHTR2AHTR6 | |
| SCHEMBL3747700 | 0.80 | PARP1 (0.62) | HTR2CHTR2AHTR6 | |
| SCHEMBL23927902 | 0.78 | HTR2C (0.64) | HTR2CHTR2AHTR6HTR1D | |
| SCHEMBL913801 | 0.78 | MPO (0.44) | HTR2CHTR2AHTR6 | |
| SCHEMBL30672847 | 0.77 | HTR2C (0.42) | HTR2CHTR2ACNR2 | |
| SCHEMBL14909548 | 0.77 | HTR2C (0.42) | HTR2CHTR2ACNR2 | |
| SCHEMBL4329685 | 0.77 | HTR2C (0.62) | HTR2CHTR2AHTR6HTR1D | |
| SCHEMBL15999003 | 0.76 | HTR2C (0.65) | HTR2CHTR2AHTR6HTR1DCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| US-8097643-B2 | Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | LABORATORIOS DEL DR. ESTEVE S. A. (ES) | 2012-01-17 | — | — | US | disclosed |
| CN-100518736-C | Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | ESTEVE LABOR DR (ES) | 2009-07-29 | — | — | CN | disclosed |
| EP-1660131-B1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | ESTEVE LABOR DR (ES) | 2009-06-24 | — | — | EP | disclosed |
| EP-1648446-B1 | INDOL-4 SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE 5-HT-6 AS MODULATORS | ESTEVE LABOR DR (ES) | 2009-06-03 | — | — | EP | disclosed |
| EP-1648468-B1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | ESTEVE LABOR DR (ES) | 2008-09-24 | — | — | EP | disclosed |
| US-20070185158-A1 | Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-08-09 | — | — | US | disclosed |
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-03-15 | — | — | US | disclosed |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-01-11 | — | — | US | disclosed |
| CN-1829508-A | Indole-4 sulfonamide derivatives, their preparation and their use as 5-HT-6 modulators | ESTEVE LABOR DR (ES) | 2006-09-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | HTR6, NPY5R, NPY2R | HTR2C 23/4885HTR2A 18/4885HTR6 1/4885 |
| US-20070185158-A1 | Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | HTR6, SLC6A4, HTR4 | HTR2C 9/4885HTR2A 18/4885HTR6 1/4885 |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, NPY5R, NPY2R | HTR2C 23/4885HTR2A 18/4885HTR6 1/4885 |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | NPY5R, HTR6, NPY2R | HTR2C 32/4885HTR2A 19/4885HTR6 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.